Select committee: Business, Innovation, Science and Trade Committee
9th Report - The impact of Brexit on the pharmaceutical sector
HC 382
Published 17 May 2018
Business, Innovation, Science and Trade Committee Brexit and the implications for UK business: Pharmaceuticals inquiry Report on parliament.uk ↗
At a glanceGovernment response published 16 July 2018
The government's response
Summary written by Accountability Index from the government's response. It is not the government's own words.
The government welcomes the report and says many of its recommendations align with its negotiating approach, while stating that it "cannot pre-judge the outcome of the negotiations".
- On a trade agreement, it is seeking "the broadest and deepest possible partnership" with the EU and is "looking for a deal that goes beyond WTO rules".
- On the European Medicines Agency, it "would like to explore the terms on which the UK could remain part of the European Medicines Agency", and says it cannot pre-judge the negotiations.
- On borders, it "recognise[s] the importance of a border that’s as frictionless as possible" and says post-exit customs arrangements "remain dependent on the outcome of UK-EU negotiations".
- On future immigration and skills, it says the Migration Advisory Committee will report in September, and it will "bring forward proposals for our future immigration system in due course".
What the committee recommended
No recommendations or conclusions have been extracted from this report. This is normal for correspondence and for special reports.
Sources
- 9th Report - The impact of Brexit on the pharmaceutical sector ↗The committee's report, HC 382, parliament.uk
- 11th Special Report - The impact of Brexit on the pharmaceutical sector: Government Response to the Committee’s Ninth Report ↗The government's response, 16 July 2018, parliament.uk